A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia

Clinical Infectious Diseases

Volumn 31, Issue 5, 2000, Pages 1155-1163

  Wingard, John R ^a   White, Mary H ^b   Anaissie, Elias ^c   Raffalli, John ^d   Goodman, Jesse ^e   Arrieta, Antonio ^f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^d WESTCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; L AMPH;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CHILD; CHILD, PRESCHOOL; CHILLS; DOUBLE-BLIND METHOD; DRUG CARRIERS; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; NAUSEA; NEUTROPENIA; SURVIVAL RATE; VOMITING;

EID: 0034456963     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317451     Document Type: Article

References (36)

1. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
2. Invasive aspergillosis
3. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases
4. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
5. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
6. Empiric antifungal therapy in febrile granulocytopenic patients
7. Empiric therapy with amphotericin B in febrile granulocytopenic patients
8. Amphotericin B: 30 years of clinical experience
9. Prospective surveillance of intravenous amphotericin B use patterns
10. Lipid formulations of amphotericin B: Recent progress and future directions
11. A comparative analysis of lipid complexed and liposomal amphotericin B preparations in haematological oncology
12. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
13. Review of the lipid-based amphotericin B products
14. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
15. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
16. Amphotericin B lipid complex (ABLC) versus amphotericin B for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial
17. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. Amphotericin B in the empirical treatment of fever and neutropenia
18. A double-blind, randomized controlled trial of amphocil (ABCD) vs. Amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients
19. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
20. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects
21. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
22. Reducing amphotericin B reactions: A double-blind study
23. Development, characterization, efficacy and mode of action of L Amph, a unilamellar liposomal formulation of amphotericin B
24. L Amph (liposomal amphotericin B): A comparative review
25. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
26. Pharmacoeconomic assessment of liposomal amphotericin B versus conventional amphotericin B deoxycholate in the empirical treatment of persistently febrile neutropenic patients
27. Prevention of amphotericin B induced renal impairment
28. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal neningitis in AIDS patients
29. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections
30. Amphotericin B lipid complex at 3 mg/kg/d for treatment of invasive fungal infections in adults with haematological malignancies
31. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
32. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
33. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers
34. Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities
35. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
36. International conference for the development of a consensus on the management and prevention of severe candidal infections